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Objectives: The aim was to analyse the population pharmacokinetics of colistin and to explore the
relationship between colistin exposure and time to death.
Methods: Patients included in the AIDA randomized controlled trial were treated with colistin for severe
infections caused by carbapenem-resistant Gram-negative bacteria. All subjects received a 9 million units
(MU) loading dose, followed by a 4.5 MU twice daily maintenance dose, with dose reduction if creatinine
clearance (CrCL) < 50 mL/min. Individual colistin exposures were estimated from the developed popu-
lation pharmacokinetic model and an optimized two-sample per patient sampling design. Time to death
was evaluated in a parametric survival analysis.
Results: Out of 406 randomized patients, 349 contributed pharmacokinetic data. The median (90% range)
colistin plasma concentration was 0.44 (0.14e1.59) mg/L at 15 minutes after the end of first infusion. In
samples drawn 10 hr after a maintenance dose, concentrations were >2 mg/L in 94% (195/208) and 44%
(38/87) of patients with CrCL 120 mL/min, and >120 mL/min, respectively. Colistin methanesulfonate
sodium (CMS) and colistin clearances were strongly dependent on CrCL. High colistin exposure to MIC
ratio was associated with increased hazard of death in the multivariate analysis (adjusted hazard ratio
(95% CI): 1.07 (1.03e1.12)). Other significant predictors included SOFA score at baseline (HR 1.24 (1.19
e1.30) per score increase), age and Acinetobacter or Pseudomonas as index pathogen.
Discussion: The population pharmacokinetic model predicted that >90% of the patients had colistin
concentrations >2 mg/L at steady state, but only 66% at 4 hr after start of treatment. High colistinator of the AIDA project.
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The currently recommended European Medicines Agency
dosing regimens for colistin are based on few data [1]. Moreover, it
is not well understood if the high variability in colistin exposures
observed betweenpatients is related to the treatment outcome. The
EU-funded (FP7) AIDA project was designed to elucidate clinical
effectiveness for old off-label antibiotics seeing resurgent use due
to increasing emergence of drug resistance [2]. One of the studies, a
multicentre, open-label, randomized controlled clinical trial, was
designed to clarify the clinical value of adding meropenem to
colistin treatment in patients with severe infections caused by
carbapenem-resistant bacteria, as earlier demonstrated in vitro [3].
The trial showed no statistically significant difference between
treatment arms in the primary endpoint success/failure, or of sur-
vival, at 14 or 28 days after randomization [4].
A secondary aim of the study was to further characterize the
population pharmacokinetics (PK) of colistin to better understand
differences between patients and relate individual exposures to
clinical outcome measures. Colistin is administered as the inactive
prodrug colistin methanesulfonate sodium (CMS), and to more
rapidly achieve colistin concentrations believed to be therapeutic, a
loading dose of 9 million units (MU) of CMS has been recom-
mended [1]. In addition to high inter-individual variability (IIV),
CMS and colistin show a high inter-occasion (day-to-day) vari-
ability (IOV) [5e7]. Creatinine clearance (CrCL) has been suggested
to explain some of the variability [7,8], but further quantification of
covariate relationships is needed to improve individualization of
CMS/colistin dosing. For example, patients with CrCL >80 mL/min
may be underexposed based on targets defined in preclinical
studies [9]. Moreover, the clinical exposureeresponse relationship
needs to be better understood to motivate dose adjustments, given
that CMS/colistin is nephrotoxic. To this end, the AIDA study pro-
vided a good basis to explore how colistin PK is related to clinical
outcomes, with population PK modelling, where information is
‘borrowed’ between individuals and the number of PK samples per
subject can be reduced to limit the logistic footprint and cost [10].
The objective of the current analysis was to characterize the
population PK in the AIDA study of critically ill patients and define
any significant covariate relationships for colistin and CMS. To this
end, a sparse PK sampling design was identified through optimal
design methodology, which focused on characterizing the indi-
vidual colistin exposure. Moreover, we explored if patient vari-
ability in colistin exposure was related to survival time in a
parametric time-to-event analysis. Such an analysis is more infor-
mative than a logistic regression analysis, e.g. survival at day 14 or
28.Patients and methods
Patients and dosing
The study was conducted according to the principles expressed
in the Declaration of Helsinki. All participating hospitals obtained
ethics approval from their respective ethics committees. Informed
consent was obtained from each eligible patient or the patient'set al., Population pharmacok
carbapenem-resistant bacterepresentative. Adults with severe infections caused by
carbapenem-non-susceptible (MIC >2 mg/L) Gram-negative bac-
teria that were susceptible to colistin by E-test or Vitek-2 (Bio-
merieux) and EUCAST susceptibility criteria at the time of inclusion
(MIC 2 mg/L for Acinetobacter baumannii and Enterobacterales
and 4 mg/L for Pseudomonas aeruginosa) were eligible [2,4]. Pa-
tient demographics have been described earlier [4]. MICs were
redone in a central laboratory using standard microdilution [11].
A colistin loading dose of 9 MU of CMS (300 mg of colistin base
activity, CBA) was administered to all patients after randomization,
independent of their CrCL value, as long as they had been on
colistin treatment for <48 hr but had not yet received a loading
dose (maximum CMS dose of 13.5 MU during 24 hr). The mainte-
nance CMS dose was 4.5 MU (150 mg of CBA) every 12 hr for pa-
tients with CrCL50 mL/min, while for patients with CrCL <50 mL/
min (without renal replacement therapy, RRT), the total daily
maintenance dose was adjusted to 2 (1.5 CrCLþ 30)/30 MU [8].
Patients with continuous RRT received a dose of 6 MU every 12 hr
and patients with intermittent haemodialysis received 1 MU every
12 hr and 1 MU of supplemental dose after dialysis. All CMS doses
were administered as 30-minute infusions immediately after
preparation of the solution.
Population pharmacokinetic modelling
Two blood samples per patient, at 45minutes and 10 hr after the
start of infusions on different dosing occasions (times defined by
optimal design [12]), were assayed for CMS and colistin (please see
supplementary material). Themost recent model by Karaiskos et al.
[13] formed the basis for the population PK analysis. Covariates
were explored for their relationship to the parameters. Patients on
RRT were not included in the model building, but their individual
exposures were predicted after adding RRT parameters [13].
Exposureeresponse analysis
The outcome assessed in the exposureeresponse analysis was
time to death, with censoring at 28 days after randomization.
Various distributions were first explored to describe the event data.
Thereafter a multivariate analysis of potential predictors was per-
formed which included demographics and variables related to pa-
tient status, infection and treatment (please see supplementary
material).
Results
Observed CMS and colistin concentrations
A total of 644 CMS concentrations and 645 colistin concentra-
tions from 349 patients were included in the PK analysis. For 57 of
the 406 patients, no concentration measurements were available
(please see supplementary material). For 48% of the patients (166/
349), both PK samples were collected within the first 24 hr after
their very first CMS dose. The median (90% range) concentration in
the 45-minute sample from these patients was 29.7 (9.8e63.9) mg/
L for CMS and 0.44 (0.14e1.59) mg/L for colistin (Fig. 1).inetics of colistin and the relation to survival in critically ill patients
ria, Clinical Microbiology and Infection, https://doi.org/10.1016/
Fig. 1. Observed CMS and colistin concentrations. Median values (black) for the first (0e7 hr after dose) and second (7e13 hr after dose) sample (in total 1289 concentrations from
349 patients) are illustrated. The nominal sampling times were 45 minutes and 10 hr after start of an infusion. The left panels show concentrations drawnwithin 24 hr after the first
(loading) dose, while the right panels show concentrations drawn after a later dose. The sample with the lowest CMS concentration at 45 minutes had also the lowest colistin
concentration.
A.N. Kristoffersson et al. / Clinical Microbiology and Infection xxx (xxxx) xxx 3Colistin concentrations determined 10 hr after a maintenance
dose were lower in patients with higher CrCL values (n ¼ 295,
Fig. 2). Patients with CrCL <50 mL/min, who had received anFig. 2. Colistin concentrations at 10 hr after a maintenance dose versus creatinine clearance
94, 62, 52 and 87, respectively. ManneWhitney U test (NS, non-significant; *p <0.05; **p >
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infected with colistin susceptible and carbapenem-resistant bacte
j.cmi.2020.03.016adjusted maintenance dose, had similar concentrations as patients
with CrCL of 50e80 mL/min. The median (90% range) colistin
concentrations at this time point was 5.4 (3.0e10.9), 4.6 (2.2e7.7),as computed by the CockcrofteGault equation. The number of patients per group was
0.01; ***p > 0.001, using R package ggsignif).
inetics of colistin and the relation to survival in critically ill patients
ria, Clinical Microbiology and Infection, https://doi.org/10.1016/
A.N. Kristoffersson et al. / Clinical Microbiology and Infection xxx (xxxx) xxx43.4 (1.1e8.0) and 1.6 (0.4e4.8) mg/L for CrCL of <50 (n¼ 94), 50e79
(n ¼ 62), 80e119 (n ¼ 52) and 120 (n ¼ 87) mL/min. In the CrCL
intervals of 50e79, 80e119 and  120 mL/min, where all patients
received the same dose, 95% (59/62), 83% (43/52) and 44% (38/87)
of the patients had a measured colistin concentration >2 mg/L, and
58% (36/62), 37% (19/52) and 11% (10/87) had a concentration >4
mg/L, in their 10-hr sample. There was no apparent change in
measured CMS or colistin exposures over the 3.5 years the trial was
conducted.
Population pharmacokinetic modelling
The final model (Fig. S1) demonstrates a good description of
both typical trends and variability of the collected CMS and colistin
concentrations (Fig. S2). CrCL based on the CockcrofteGault for-
mula was the only included covariate but was found to be signifi-
cant (p < 0.001) for both CMS clearance and apparent colistin
clearance, and decreased variability from 45% to 13% (CMS clear-
ance) and 36% to 24% (colistin clearance) (Table S1). Modification of
Diet in Renal Disease (MDRD), in combination with body weight,
resulted in worse description of the data than CrCL alone and was
therefore not selected. In the final model, the typical colistin half-
lives were estimated to 25, 17 and 12 hr, for patients with CrCL of
50, 80 and 120 mL/min, respectively.
The model predicts that for the dose regimen used here (9 MU
loadþ 4.5MU every 12 hrmaintenance dose), a typical patient with
CrCL of 50, 80, 120 and 180 mL/min will have an average colistin
concentration during the first 120 hr of 6.4, 4.4, 3.0 and 1.8 mg/L,
respectively (Fig. 3). The corresponding predicted percentages of
patients with average concentrations >2 and > 4 mg/L are 100%,
100%, 97% and 30% and 99%, 69%, 5.4% and 0%, respectively. The
patients' predicted colistin fAUC24h/MIC was 0.2e169 (median of
25), for a free fraction of 34% (determined in plasma from critically
ill patients and a colistin A to colistin B ratio similar to the clinically
available CMS product [7]).
Exposureesurvival analysis
The time-to-death analysis included all 406 patients. The events
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Fig. 3. Predicted total colistin concentrations from the developed model for a range of CrCL
creatinine clearance <50 mL/min received an adjusted maintenance dose.
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j.cmi.2020.03.016suggesting a peak in the hazard of death on day 4 after randomi-
zation. Univariate analysis results of evaluated predictors are pre-
sented in Table S2. Multivariate analysis (Table 1) resulted in the
following four significant predictors, included in the order
mentioned (HR > 1 associated with increased risk of fatality): (a)
SOFA score at randomization (p < 0.001, adjusted HR 1.20
(1.15e1.25)), (b) age of the subject (p < 0.001, adjusted HR 1.02
(1.01e1.03)), (c) the infecting pathogen not being Acinetobacter or
Pseudomonas aeruginosa (p < 0.01, adjusted HR 0.49 (0.33e0.83))
and (d) the ratio between average colistin concentrations over
5 days (Cavg,120h) and colistin MIC (p < 0.001, adjusted HR 1.07
(1.03e1.12)). Variables of renal function (Table S2) were not better
predictors than Cavg,120h/MICcolistin. Neither was an interaction be-
tween CrCL and Cavg,120h/MICcolistin significant. The same four pre-
dictors were identified when subjects on RRT (n ¼ 38) were
excluded from the analysis. When subjects without PK samples or
centrally determined MICs (n ¼ 112) were excluded from the
analysis, pathogen type was no longer significant. Simulations from
the final parametric time-to-death model captured the observed
data and the trends of the included predictors (Fig. 4).
Discussion
This population PK analysis of CMS and colistin included 349
patients (319 patients not on RRT) and is, to our knowledge, the
largest patient cohort studied up to date regarding CMS and colistin
PK. Included patients had a large spread in renal function (median
CrCL of 70 mL/min (IQR 38e137 mL/min, range 9e658 mL/min) for
non-RRT patients) and both CMS and colistin clearances were
highly correlated to CrCL. The applied dosing regimen of a 9 MU
loading dose followed by a 4.5 MU every 12 hr maintenance dose
resulted in colistin concentrations above the suggested PK/PD
target [9] and the current EUCAST breakpoint of 2 mg/L for the
majority of the studied patients, at 22 hr after start of colistin
treatment. Surprisingly, the colistin concentration over MIC ratio
was not associated with survival, but rather with hazard of fatality.
At 45 minutes after the start of the loading dose infusion, the
measured colistin concentrationwas low (median 0.44mg/L), which
illustrates that the conversionofCMSto colistinwasnot immediate in










values. The same dosing formula as in the AIDA study was applied where patients with
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Table 1
Parameter estimates of the final time-to-event model (406 patients) from the multivariate analysis
Model parameter (unit) Explanation of model parameter Estimate, relative standard error (%) Hazard ratio (95% CI)
p Shape parameter 2.43 (20) d
l Scale parameter 0.119 (11) d
g Scale parameter 0.298 (16) d
q1 (-) SOFA score at randomization (per point)a 0.181 (12) 1.20 (1.15e1.25)
q2 (year1) Age (per year)a 0.022 (25) 1.02 (1.01e1.03)
q3 (-) Index isolate other than Acinetobacter or Pseudomonasa e0.650 (36) 0.49 (0.33e0.83)
q4 (-) Cavg,120h/MICcolistina 0.072 (27) 1.07 (1.03e1.12)
The relative standard error is a measure of howwell estimated the parameter is. Base hazard function: h0ðtÞ ¼
lpðltÞp1
ð1þ ðgtÞpÞwhere p is the shape parameter, and l and g are scale
parameters.
a Covariates were added on the hazard function:
hðtÞ ¼ h0ðtÞ eq1ðSOFA6Þþq2ðAge65Þþq3No Acinetobacter Pseudomonasþq4ðcavg; 120h=MICcolistin5Þ , where qi is the covariate coefficient.
Fig. 4. Model evaluation of the final time-to-event model of survival. KaplaneMeier Visual Predictive Check of the overall model (top left), and stratified for bacteria type (middle
left and middle right) and KaplaneMeier mean covariate plot [24] for SOFA score (top right), age (lower left) and ratio between average colistin concentration and MIC (lower right)
where the means of the covariates on the y-axes are computed for those patients remaining in the trial at the times of events. The black lines illustrate the observed data, and the
shaded intervals represent the 95% confidence intervals based on simulations from the developed model.
A.N. Kristoffersson et al. / Clinical Microbiology and Infection xxx (xxxx) xxx 5concentrations 2 mg/L, but without a loading dose the corre-
sponding numberwould have been7%, and itwould have taken 25hr
before 66 % of the patients reached the same concentration target.Please cite this article as: Kristoffersson AN et al., Population pharmacok
infected with colistin susceptible and carbapenem-resistant bacte
j.cmi.2020.03.016Nevertheless, for indications such as bloodstream infection, the delay
in formation of active drug, even after administration of a loading
dose, might be a shortcoming for treatment with colistin. The doseinetics of colistin and the relation to survival in critically ill patients
ria, Clinical Microbiology and Infection, https://doi.org/10.1016/
A.N. Kristoffersson et al. / Clinical Microbiology and Infection xxx (xxxx) xxx6reduction formula for patients with CrCL <50 mL/min [8] resulted in
similar concentrations as for patients with CrCL of 50e80 mL/min
(Fig. 2), while amore recent dose adjustment formula [9] would have
resulted in higher concentrations.
The current study shows that the high failure rate and mortality
observed in the AIDA trial [4] is likely not to be due to underdosing
or failure to achieve the suggested PKPD target of 2 mg/L [9].
Moreover, of patients with both PK and colistin MIC determined,
74% (250/336) had an AUC24h/MIC 48. It should be noted that
these targets are based on studies in mouse thigh infection models
[15], while 55% of the patients in AIDA had pneumonia. Indeed,
stasis was not achievable in the mouse lung model for two out of
three strains (MICs of 0.5e1 mg/L) of A. baumannii [15], the most
common bacterial species in the trial. We also identified
A. baumannii (and P. aeruginosa) to be related to higher hazard of
death than infections with e.g. Klebsiella pneumoniae (Table 1).
Moreover, the freely available concentration of colistin in lung
might be low because of poor distribution [16,17] or binding to
mucin in lung fluids [18]. When the relationship between colistin
concentration (or colistin concentration to MIC ratio) and the
hazard of death was explored to be U-shaped to allow for reduced
hazard at target concentrations of 2e4 mg/L, there was no signifi-
cant improvement in the model fit.
As anticipated, patient characteristics, best described by SOFA
score, was the most significant variable predicting time to death.
That a low colistin exposure (i.e. low Cavg,120h/MICcolistin ratio) was
associated with survival, even after correction for SOFA score, age
and pathogen, is in line with an earlier study in 59 patients [19]
where SOFA score and colistin concentrations were higher in pa-
tients who failed therapy. Their measured colistin trough con-
centrations (though reported as Css,avg [19]) were however lower
than the 10-hr post-dose concentrations observed here. This is
likely to be primarily because of lower daily CMS dosing (median 3
MU) and extended dosing intervals (up to 36 hr). Their patients
also had a median SOFA score of 2 vs 6 in the current study. These
studies taken together indicate that individualized colistin
dosage, guided by colistin exposure in blood, may not necessarily
improve the outcome. It should also be acknowledged that re-
sidual confounding cannot be ruled out in both studies. To fully
elucidate the exposureeresponse relationship, a study random-
ized by dose or concentration would be required, which is not
feasible in practice.
Population PK analyses of colistin have earlier been reported in
critically ill patients [5e8,20]. Different parameterizations (e.g.
CrCL relationships) make comparisons of apparent colistin CL es-
timates difficult, but analyses of studies conducted a decade ago
generally predict lower concentrations than analyses based on
more recently conducted trials. This may at least partly be because
of the lower fraction of measurable colistin components in earlier
formulations [21] than in current products [7] (2nd International
Conference on Polymyxins, Abstract P-2). For a patient with a CrCL
of 80 mL/min, the current study predicts an average steady-state
colistin concentration of 4.4 mg/L, for in total 9 MU per day,
which is somewhat higher than relatively recent studies of 3.4 [20]
and 2.7 [7] mg/L, but lower than Magreault et al. (4.3 mg/L; 28th
European Congress of Clinical Microbiology and Infectious Diseases,
Abstract P2232) considering their average CrCL of 99mL/min. Inter-
study difference might also be associated with patient status,
although here CrCL was a better covariate than SOFA score for
colistin clearance. A relationship between colistin clearance and
CrCL has indeed earlier been suggested [8] despite the fact that
polymyxins are eliminated by renal excretion only to a minor
extent [9]. CrCL reflects however the overall kidney function, and,
as for other peptides, the kidney may be an essential site for
degradation of colistin [22].Please cite this article as: Kristoffersson AN et al., Population pharmacok
infected with colistin susceptible and carbapenem-resistant bacte
j.cmi.2020.03.016Cavg,120h/MICcolistin was a superior predictor of fatality than all
renal function variables tested, indicating that colistin exposure
may better reflect prognosis. When CrCL was the only predictor in
the model, and this relationship was fixed, the addition of Cavg,120h/
MICcolistin did not reach statistical significance, indicating over-
lapping explanatory value. Future analyses of AIDA trial data may
guide how to reduce the risk for colistin-induced acute kidney
injury [23]. If individual dose adjustments based on concentration
measurements are to be performed, the here identified sampling
time points of 45 minutes and 10 hr are recommended when both
colistin and CMS can be reliably assayed.
To conclude, the observed colistin concentrations were >2 mg/
L in the majority of patients with CrCL <120 mL/min, while for
patients with CrCL 120 mL/min higher doses would be needed to
achieve the same exposure. The population PK model identified
that both CMS and colistin clearances are highly correlated to
CrCL, and explained parts of the variability in the exposure be-
tween patients. Patient health status, rather than colistin expo-
sure, seems however most critical for treatment success in
vulnerable patient populations such as the one studied in the
colistin AIDA trial.Transparency Declaration
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